BioSpace News Archive

Andera Life Sciences, the business line specialising in innovative therapeutics and medical technologies of the asset management company Andera Partners, has announced the finalisation of its fundraising for its BioDiscovery 6 fund at 456 million euros.

Jaswinder Grover, MD, Board-certified orthopedic and spine surgeon with more than 25 years of experience in the medical field, has been appointed to the Medical Advisory Board of Harvard MedTech.

Synaptive Medical Inc. announced a joint-development partnership with bioelectronic medicine company Panaxium SAS to incorporate Panaxium’s ultra-flexible iontronic electrocorticography platform into Synaptive’s Modus V robotic exoscope technology.

Cala announced that the Centers for Medicare & Medicaid Services has set a payment determination and benefit category for the existing unique Healthcare Common Procedure Coding System code K1018 for Cala TAPS therapy, initially put into effect in 2021.

Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) is pleased to announce a Pre-Investigational New Drug (“Pre-IND”) meeting granted by the U.S. Food and Drug Administration (the “FDA”) for the Company’s new chemical entity (“NCE”) Triptax™.

DICE Therapeutics, Inc. (Nasdaq: DICE) today announced positive topline data from its Phase 1 clinical trial of DC-806, an oral small molecule antagonist of the pro-inflammatory cytokine IL-17.

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or the ‘Company’) is pleased to announce that it has completed a constructive pre-Investigational New Drug Application (‘pre-IND’) meeting with the U.S. Food and Drug Administration (‘FDA’) for its proprietary drug product IHL-216A for treatment of traumatic brain injury and concussion (‘TBI’).

Lipocine Inc announced today that it will present at the H.C. Wainwright 6th Annual NASH Investor Conference to be held virtually on October 17.

Eiger BioPharmaceuticals, Inc. today announced that David Cory , President and CEO, will present a company overview at the H.C. Wainwright Third Annual Hepatitis B Virus (HBV) Virtual Conference on Tuesday, October 18, 2022 at 3:00 PM ET.

For pathfinders in cell and gene therapy striving to accelerate next-generation care, Invetech delivers robust, scalable and cost-effective manufacturing systems for clinical through to high-volume commercial production. Since 2003